AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
The COVID-19 pandemic began at an unprecedented time when humans, organizations and institutes were not prepared. Like the global cases and deaths, Cuba had a recurring cases and deaths totaling 70,000 and 408 respectively as at March 2021 (Yaffe, 2021). The severity of cases and the resulting deaths influenced the production of COVID-19 vaccine in...
Symptoms of abnormal cervical cells are often non-specific, making it challenging to determine the severity of the underlying condition based solely on symptoms. Despite their non-specific nature, these symptoms are crucial in guiding medical investigations towards an accurate diagnosis. Regular checkups are essential for timely detection of potentially malignant pathologies, regardless of the presence of...
Cuba offers a carefully tailored program for individuals suffering from autism spectrum disorder (ASD). The main goal of this program is to improve the child’s learning capabilities and reduce the symptoms of ASD. Overall, the program aims to boost the development capacity of each child with ASD. As a result, a visible improvement is seen...
Cuba is undergoing a transformation in its health services and the guidelines governing said services. The transformation focuses on the analysis of the most persistent challenges in the country, and the implementation of economic and social policies to address them.Several changes have been implemented occurred and are looking at this perspective, and within them, new...
Nimotuzumab is a cutting-edge monoclonal antibody therapy designed to treat various epithelial cancers, including head and neck cancer, glioma, and non-small cell lung cancer (NSCLC). Developed with advanced biotechnology, Nimotuzumab offers a targeted approach to cancer therapy, minimizing side effects while maximizing efficacy. This document explores Nimotuzumab’s mechanism, clinical outcomes, and benefits, underscoring its role...
Vaxira (Racotumomab) is an innovative therapeutic vaccine developed to treat non-small cell lung cancer (NSCLC). This groundbreaking therapy, originating from Cuban research, targets a specific cancer cell marker, offering a novel approach to treatment. This document delves into the scientific basis, clinical efficacy, and numerous benefits of Vaxira, highlighting its potential in revolutionizing cancer treatment....
CimaVax is a cutting-edge therapeutic vaccine developed in Cuba, designed to treat non-small cell lung cancer (NSCLC). This vaccine targets the epidermal growth factor (EGF), a critical protein involved in cancer cell proliferation. CimaVax has garnered international recognition due to its unique mechanism of action, cost-efficiency, and promising clinical results. This document provides an in-depth...